Skip to main content
SpringerLink
Log in

Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review

  • Systematic Review
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Background

Facial seborrheic dermatitis (SD), a chronic inflammatory skin condition, can impact quality of life, and relapses can be frequent. Three broad categories of agents are used to treat SD: antifungal agents, keratolytics, and corticosteroids. Topical therapies are the first line of defense in treating this condition.

Objective

Our objective was to critically review the published literature on topical treatments for facial SD.

Methods

We searched PubMed, Scopus, Clinicaltrials.gov, MEDLINE, Embase, and Cochrane library databases for original clinical studies evaluating topical treatments for SD. We then conducted both a critical analysis of the selected studies by grading the evidence and a qualitative comparison of results among and within studies.

Results

A total of 32 studies were eligible for inclusion, encompassing 18 topical treatments for facial SD. Pimecrolimus, the focus of seven of the 32 eligible studies, was the most commonly studied topical treatment.

Conclusion

Promiseb®, desonide, mometasone furoate, and pimecrolimus were found to be effective topical treatments for facial SD, as they had the lowest recurrence rate, highest clearance rate, and the lowest severity scores (e.g., erythema, scaling, and pruritus), respectively. Ciclopirox olamine, ketoconazole, lithium (gluconate and succinate), and tacrolimus are also strongly recommended (level A recommendations) topical treatments for facial SD, as they are consistently effective across high-quality trials (randomized controlled trials).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Araya M, Kulthanan K, Jiamton S. Clinical characteristics and quality of life of seborrheic dermatitis patients in a tropical country. Indian J Dermatol. 2015;60(5):519.

    PubMed  PubMed Central  Google Scholar 

  2. Berk T, Scheinfeld N. Seborrheic dermatitis. Pharm Ther. 2010;35(6):348.

    Google Scholar 

  3. Stefanaki I, Katsambas A. Therapeutic update on seborrheic dermatitis. Skin Ther Lett. 2010;15(5):1–4.

    CAS  Google Scholar 

  4. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006;74(1):125–30.

    PubMed  Google Scholar 

  5. Halder RM, Nootheti PK. Ethnic skin disorders overview. J Am Acad Dermatol. 2003;48(6 Suppl):S143–8.

    Article  PubMed  Google Scholar 

  6. Del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. J Clin Aesthetic Dermatol. 2011;4(5):32–8.

    Google Scholar 

  7. Kastarinen H, Oksanen T, Okokon EO, Kiviniemi VV, Airola K, Jyrkkä J, et al. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database Syst Rev. 2014;5:CD009446.

    Google Scholar 

  8. Hay RJ. Malassezia, dandruff and seborrhoeic dermatitis: an overview. Br J Dermatol. 2011;165(Suppl 2):2–8.

    Article  PubMed  Google Scholar 

  9. Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol JEADV. 2004;18(1):13–26 (quiz 19–20).

    Article  CAS  PubMed  Google Scholar 

  10. Ortonne JP, Lacour JP, Vitetta A, Le Fichoux Y. Comparative study of ketoconazole 2 % foaming gel and betamethasone dipropionate 0.05 % lotion in the treatment of seborrhoeic dermatitis in adults. Dermatol Basel Switz. 1992;184(4):275–80.

    Article  CAS  Google Scholar 

  11. Tanaka A, Cho O, Saito C, Saito M, Tsuboi R, Sugita T. Comprehensive pyrosequencing analysis of the bacterial microbiota of the skin of patients with seborrheic dermatitis. Microbiol Immunol. 2016;60(8):521–6.

    Article  CAS  PubMed  Google Scholar 

  12. Johnson BA, Nunley JR. Treatment of seborrheic dermatitis. Am Fam Physician 2000;61(9):2703–10, 2713–4.

  13. Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015;91(3):185–90.

    PubMed  Google Scholar 

  14. Misery L, Touboul S, Vinçot C, Dutray S, Rolland-Jacob G, Consoli S-G, et al. Stress and seborrheic dermatitis. Ann Dermatol Vénéréologie. 2007;134(11):833–7.

    Article  CAS  Google Scholar 

  15. Gupta AK, Madzia SE, Batra R. Etiology and management of Seborrheic dermatitis. Dermatol Basel Switz. 2004;208(2):89–93.

    Article  Google Scholar 

  16. Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med. 2009;360(4):387–96.

    Article  CAS  PubMed  Google Scholar 

  17. Choeng WK, Yeung CK, Torsekar RG, Suh DH, Ungpakorn R, Widaty S, et al. Treatment of seborrhoeic dermatitis in Asia: a consensus guide. Skin Appendage Disord. 2015;1:187–96.

    Article  Google Scholar 

  18. Chatzikokkinou P, Sotiropoulos K, Katoulis A, Luzzati R, Trevisan G. Seborrheic dermatitis—an early and common skin manifestation in HIV patients. Acta Dermatovenerol Croat ADC. 2008;16(4):226–30.

    PubMed  Google Scholar 

  19. Cribier B, Samain F, Vetter D, Heid E, Grosshans E. Systematic cutaneous examination in hepatitis C virus infected patients. Acta Derm Venereol. 1998;78(5):355–7.

    Article  CAS  PubMed  Google Scholar 

  20. Barba A, Piubello W, Vantini I, Caliari S, Cocchetto R, Vallaperta P, et al. Skin lesions in chronic alcoholic pancreatitis. Dermatologica. 1982;164(5):322–6.

    Article  CAS  PubMed  Google Scholar 

  21. Tegner E. Seborrhoeic dermatitis of the face induced by PUVA treatment. Acta Derm Venereol. 1983;63(4):335–9.

    CAS  PubMed  Google Scholar 

  22. Szepietowski JC, Reich A, Wesołowska-Szepietowska E, Baran E, National Quality of Life in Dermatology Group. Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses. 2009;52(4):357–63.

    Article  PubMed  Google Scholar 

  23. Elewski B. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05 % in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clin Dermatol 2009;27(6 Suppl):S48–53.

  24. Bikowski J. Facial seborrheic dermatitis: a report on current status and therapeutic horizons. J Drugs Dermatol JDD. 2009;8(2):125–33.

    PubMed  Google Scholar 

  25. Berg D, Plempel M. Bifonazole, a biochemist’s view. Dermatologica. 1984;169(Suppl 1):3–9.

    Article  CAS  PubMed  Google Scholar 

  26. Gupta AK, Batra R, Nicol K. Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol. 2004;5(6):417–22.

    Article  PubMed  Google Scholar 

  27. Baysal V, Yildirim M, Ozcanli C, Ceyhan AM. Itraconazole in the treatment of seborrheic dermatitis: a new treatment modality. Int J Dermatol. 2004;43(1):63–6.

    Article  CAS  PubMed  Google Scholar 

  28. Cook BA, Warshaw EM. Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. Am J Clin Dermatol. 2009;10(2):103–18.

    Article  PubMed  Google Scholar 

  29. Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venereol JEADV. 2014;28(1):16–26.

    Article  CAS  PubMed  Google Scholar 

  30. Gupta AK, Kogan N. Seborrhoeic dermatitis: current treatment practices. Expert Opin Pharmacother. 2004;5(8):1755–65.

    Article  CAS  PubMed  Google Scholar 

  31. Abbas Z, Ghodsi SZ, Abedeni R. Effect of itraconazole on the quality of life in patients with moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial. Dermatol Pract Concept. 2016;6(3):11–6.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev. 2015;5:CD008138.

    Google Scholar 

  33. Wat H, Wu DC, Rao J, Goldman MP. Application of intense pulsed light in the treatment of dermatologic disease: a systematic review. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2014;40(4):359–77.

    CAS  Google Scholar 

  34. Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract Am Board Fam Pract. 2004;17(1):59–67.

    Article  Google Scholar 

  35. Byeon SW, Pelley RP, Ullrich SE, Waller TA, Bucana CD, Strickland FM. Aloe barbadensis extracts reduce the production of interleukin-10 after exposure to ultraviolet radiation. J Invest Dermatol. 1998;110(5):811–7.

    Article  CAS  PubMed  Google Scholar 

  36. Vardy D, Cohen A, Tchetov T, Medvedovsky E, Biton A. A double-blind, placebo-controlled trial of an Aloe vera (A. barbadensis) emulsion in the treatment of seborrheic dermatitis. J Dermatol Treat 1998;10:7–11.

    Article  Google Scholar 

  37. Carson CF, Riley TV. Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia. J Appl Bacteriol. 1995;78(3):264–9.

    Article  CAS  PubMed  Google Scholar 

  38. Nenoff P, Haustein UF, Brandt W. Antifungal activity of the essential oil of Melaleuca alternifolia (tea tree oil) against pathogenic fungi in vitro. Skin Pharmacol Off J Skin Pharmacol Soc. 1996;9(6):388–94.

    CAS  Google Scholar 

  39. Caldefie-Chézet F, Fusillier C, Jarde T, Laroye H, Damez M, Vasson M-P, et al. Potential anti-inflammatory effects of Melaleuca alternifolia essential oil on human peripheral blood leukocytes. Phytother Res PTR. 2006;20(5):364–70.

    Article  PubMed  Google Scholar 

  40. Beheshti RA, Tavakoli-far B, Fallah HH, Tousi P, Shafigh N, Rahimzadeh M. Efficacy of Melaleuca alternifolia essential oil in the treatment of facial seborrheic dermatitis: a double-blind, randomized, placebo-controlled clinical trial. J Med Plants. 2014;13(51):26–32.

    Google Scholar 

  41. Toma W, Gracioso JS, Hiruma-Lima CA, Andrade FDP, Vilegas W, Souza Brito ARM. Evaluation of the analgesic and antiedematogenic activities of Quassia amara bark extract. J Ethnopharmacol. 2003;85(1):19–23.

    Article  CAS  PubMed  Google Scholar 

  42. Diehl C, Ferrari A. Efficacy of topical 4 % Quassia amara gel in facial seborrheic dermatitis: a randomized, double-blind, comparative study. J Drugs Dermatol JDD. 2013;12(3):312–5.

    PubMed  Google Scholar 

  43. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol. 2001;2(2):95–120.

    Article  CAS  PubMed  Google Scholar 

  44. Berth-Jones J, Adnitt P. Topical calcipotriol is not effective in facial seborrhoeic dermatitis. J Dermatol Treat. 2001;12:179.

    Article  CAS  Google Scholar 

  45. Kragballe K. Treatment of psoriasis with calcipotriol and other vitamin D analogues. J Am Acad Dermatol. 1992;27(6 Pt 1):1001–8.

    Article  CAS  PubMed  Google Scholar 

  46. Tadaki T, Kato T, Tagami H. Topical active vitamin D3 analogue, 1,24-dihydroxycholecalciferol, an effective new treatment for facial seborrhoeic dermatitis. J Dermatol Treat. 1996;7:139–41.

    Article  Google Scholar 

  47. Shalita AR, Smith JG, Parish LC, Sofman MS, Chalker DK. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol. 1995;34(6):434–7.

    Article  CAS  PubMed  Google Scholar 

  48. Fabbrocini G, Cantelli M, Monfrecola G. Topical nicotinamide for seborrheic dermatitis: an open randomized study. J Dermatol Treat. 2014;25(3):241–5.

    Article  CAS  Google Scholar 

  49. Papp KA, Papp A, Dahmer B, Clark CS. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1 % ointment compared with tacrolimus 0.1 % ointment in adults. J Am Acad Dermatol. 2012;67(1):e11–5.

    Article  CAS  PubMed  Google Scholar 

  50. Kim T-W, Mun J-H, Wa S-WJ, Song M, Kim H-S, Ko H-C, et al. Proactive treatment of adult facial seborrheic dermatitis with 0.1 % tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-center trial. Acta Derm Venereol. 2013;93:557–61.

    Article  PubMed  Google Scholar 

  51. Kim HO, Yang YS, Ko HC, Kim GM, Cho SH, Seo YJ, et al. Maintenance therapy of facial seborrheic dermatitis with 0.1 % tacrolimus ointment. Ann Dermatol. 2015;27(5):523–30.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999;141(2):264–73.

    Article  CAS  PubMed  Google Scholar 

  53. Firooz A, Solhpour A, Gorouhi F, Daneshpazhooh M, Balighi K, Farsinejad K, et al. Pimecrolimus cream, 1 %, vs hydrocortisone acetate cream, 1 %, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol. 2006;142(8):1066–7.

    Article  PubMed  Google Scholar 

  54. Ozden MG, Tekin NS, Ilter N, Ankarali H. Topical pimecrolimus 1 % cream for resistant seborrheic dermatitis of the face: an open-label study. Am J Clin Dermatol. 2010;11(1):51–4.

    Article  PubMed  Google Scholar 

  55. Kim B-S, Kim S-H, Kim M-B, Oh C-K, Jang H-S, Kwon K-S. Treatment of facial seborrheic dermatitis with pimecrolimus cream 1 %: an open-label clinical study in Korean patients. J Korean Med Sci. 2007;22(5):868–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1 % vs. betamethasone 17-valerate 0.1 % cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol. 2004;151(5):1071–5.

    Article  CAS  PubMed  Google Scholar 

  57. Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1 % cream and topical ketoconazole 2 % cream in the treatment of seborrheic dermatitis. J Dermatol Treat. 2009;20(1):4–9.

    Article  CAS  Google Scholar 

  58. Cicek D, Kandi B, Bakar S, Turgut D. Pimecrolimus 1 % cream, methylprednisolone aceponate 0.1 % cream and metronidazole 0.75 % gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatol Treat. 2009;20(6):344–9.

    Article  CAS  Google Scholar 

  59. Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1 % for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007;57(2):257–64.

    Article  PubMed  Google Scholar 

  60. Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol. 1997;36(10):788–92.

    Article  CAS  PubMed  Google Scholar 

  61. Unholzer A, Schinzel S, Nietsch K-H, Jung GE, Korting HC. Ciclopiroxolamine cream 1 % in the treatment of seborrhoeic dermatitis: a double-blind, parallel-group comparison with ketoconazole and vehicle in a confirmatory trial. Clin Drug Invest. 2002;22(3):167–72.

    Article  CAS  Google Scholar 

  62. Chosidow O, Maurette C, Dupuy P. Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1 % cream and ketoconazole 2 % foaming gel in mild to moderate facial seborrheic dermatitis. Dermatol Basel Switz. 2003;206(3):233–40.

    Article  CAS  Google Scholar 

  63. Liebel F, Lyte P, Garay M, Babad J, Southall MD. Anti-inflammatory and anti-itch activity of sertaconazole nitrate. Arch Dermatol Res. 2006;298(4):191–9.

    Article  CAS  PubMed  Google Scholar 

  64. Carrillo-Muñoz AJ, Giusiano G, Ezkurra PA, Quindós G. Sertaconazole: updated review of a topical antifungal agent. Expert Rev Anti Infect Ther. 2005;3(3):333–42.

    Article  PubMed  Google Scholar 

  65. Elewski BE, Cantrell WC. An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis. J Drugs Dermatol JDD. 2011;10(8):895–9.

    CAS  PubMed  Google Scholar 

  66. Zienicke H, Korting HC, Braun-Falco O, Effendy I, Hagedorn M, Küchmeister B, et al. Comparative efficacy and safety of bifonazole 1 % cream and the corresponding base preparation in the treatment of seborrhoeic dermatitis. Mycoses. 1993;36(9–10):325–31.

    CAS  PubMed  Google Scholar 

  67. Faergemann J. Treatment of seborrhoeic dermatitis with bifonazole. Mycoses. 1989;32(6):309–11.

    Article  CAS  PubMed  Google Scholar 

  68. Pfizer. Diflucan tablets (Fluconazole) Label Information [Internet]. 2011 [cited 2012 May 30]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s055,019950s059,020090s038lbl.pdf.

  69. Rigopoulos D, Katsambas A, Antoniou C, Theocharis S, Stratigos J. Facial seborrheic dermatitis treated with fluconazole 2 % shampoo. Int J Dermatol. 1994;33(2):136–7.

    Article  CAS  PubMed  Google Scholar 

  70. Van Cutsem J. The antifungal activity of ketoconazole. Am J Med. 1983;74(1B):9–15.

    Article  PubMed  Google Scholar 

  71. Van Cutsem J, Van Gerven F, Cauwenbergh G, Odds F, Janssen PA. The antiinflammatory effects of ketoconazole. A comparative study with hydrocortisone acetate in a model using living and killed Staphylococcus aureus on the skin of guinea-pigs. J Am Acad Dermatol. 1991;25(2 Pt 1):257–61.

    Article  PubMed  Google Scholar 

  72. Green CA, Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol. 1987;116(2):217–21.

    Article  CAS  PubMed  Google Scholar 

  73. Elocon (mometasone furoate) Ointment, 0.1 % for topical use [Internet]. FDA US Food Drug Adm. 2013 [cited 2016 May 26]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf.

  74. Medansky R, Lepaw M, Shavin J, Zimmerman E, Jones M, Peets E, et al. Mometasone furoate cream 0.1 % vs. hydrocortisone cream 1 % in the treatment of seborrheic dermatitis. J Dermatol Treat. 1992;3:125–8.

    Article  Google Scholar 

  75. Kurita N, Funabashi M. Growth-inhibitory effect on fungi of alkali cations and monovalent inorganic anions and antagonism among different alkali cations. Agric Biol Chem. 1984;48(4):887–93.

    CAS  Google Scholar 

  76. Nassar A, Azab AN. Effects of lithium on inflammation. ACS Chem Neurosci. 2014;5(6):451–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Dreno B, Chosidow O, Revuz J, Moyse D, STUDY INVESTIGATOR GROUP. Lithium gluconate 8 % vs ketoconazole 2 % in the treatment of seborrhoeic dermatitis: a multicentre, randomized study. Br J Dermatol. 2003;148(6):1230–6.

    Article  CAS  PubMed  Google Scholar 

  78. Boyle J, Burton JL, Faergemann J. Use of topical lithium succinate for seborrhoeic dermatitis. Br Med J Clin Res Ed. 1986;292(6512):28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Schlesinger T, Rowland Powell C. Efficacy and safety of a low molecular weight hyaluronic acid topical gel in the treatment of facial seborrheic dermatitis final report. J Clin Aesthetic Dermatol. 2014;7(5):15–8.

    Google Scholar 

  80. Siadat AH, Iraji F, Shahmoradi Z, Enshaieh S, Taheri A. The efficacy of 1 % metronidazole gel in facial seborrheic dermatitis: a double blind study. Indian J Dermatol Venereol Leprol. 2006;72(4):266–9.

    Article  PubMed  Google Scholar 

  81. Seckin D, Gurbuz O, Akin O. Metronidazole 0.75 % gel vs. ketoconazole 2 % cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study. J Eur Acad Dermatol Venereol JEADV. 2007;21(3):345–50.

    Article  CAS  PubMed  Google Scholar 

  82. Koca R, Altinyazar HC, Eştürk E. Is topical metronidazole effective in seborrheic dermatitis? A double-blind study. Int J Dermatol. 2003;42(8):632–5.

    Article  CAS  PubMed  Google Scholar 

  83. de Moraes AP, de Arruda EAG, Vitoriano MAV, de Moraes Filho MO, Bezerra FAF, de Magalhães Holanda E, et al. An open-label efficacy pilot study with pimecrolimus cream 1 % in adults with facial seborrhoeic dermatitis infected with HIV. J Eur Acad Dermatol Venereol JEADV. 2007;21(5):596–601.

    PubMed  Google Scholar 

  84. Langtry JA, Rowland Payne CM, Staughton RC, Stewart JC, Horrobin DF. Topical lithium succinate ointment (Efalith) in the treatment of AIDS-related seborrhoeic dermatitis. Clin Exp Dermatol. 1997;22(5):216–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Toronto, Toronto, ON, Canada

    Aditya K. Gupta

  2. Mediprobe Research Inc., 645 Windermere Road, London, ON, Canada

    Aditya K. Gupta & Sarah G. Versteeg

Authors
  1. Aditya K. Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah G. Versteeg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aditya K. Gupta.

Ethics declarations

Funding

No funding was received for the preparation of this review.

Conflict of interest

AK Gupta and SG Versteeg have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gupta, A.K., Versteeg, S.G. Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. Am J Clin Dermatol 18, 193–213 (2017). https://doi.org/10.1007/s40257-016-0232-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-016-0232-2

Search

Navigation